Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Non-Myeloablative Allogeneic PBSC Transplant for Hematologic Diseases
NCT00003838Phase 2Completed
- Sponsor
- National Heart, Lung, and Blood Institute
- Start
- Apr 1999
- Primary completion
- Dec 2018
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of peripheral blood stem cells in chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML) and 12 more (2 arms), sponsored by National Heart, Lung, and Blood Institute. Primary endpoint: Transplant Related Mortality at 200 days. Started Apr 1999; status: completed.
02
Drugs
peripheral blood stem cells
03
Conditions
chronic myeloid leukemia (CML)acute lymphoblastic leukemia (ALL)acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)myeloproliferative neoplasms (MPN)
Beyond the preview
Go deeper on NCT00003838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003838.